Literature DB >> 17768503

Unfulfilled potential: using diethylcarbamazine-fortified salt to eliminate lymphatic filariasis.

Patrick Lammie1, Trevor Milner, Robin Houston.   

Abstract

Fortifying salt with diethylcarbamazine (DEC) is a safe, low-cost and effective strategy to eliminate transmission of lymphatic filariasis. DEC-fortified salt has been used successfully in pilot projects in several countries and has been used operationally by China to eliminate lymphatic filariasis. The successful use of iodized salt to eliminate iodine-deficiency disorders is encouraging; similarly, fortified salt could be used as a vehicle to eliminate lymphatic filariasis. Despite the potential programmatic advantages of fortifying salt with DEC instead of undertaking mass administration of tablets, DEC-fortified salt remains an underutilized intervention. We discuss the reasons for this and suggest settings in which the use of DEC-fortified salt should be considered.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17768503      PMCID: PMC2636360          DOI: 10.2471/blt.06.034108

Source DB:  PubMed          Journal:  Bull World Health Organ        ISSN: 0042-9686            Impact factor:   9.408


  41 in total

Review 1.  Diethylcarbamazine in the treatment of patients with onchocerciasis.

Authors:  K Awadzi; H M Gilles
Journal:  Br J Clin Pharmacol       Date:  1992-10       Impact factor: 4.335

2.  Advancement of global health: key messages from the Disease Control Priorities Project.

Authors:  Ramanan Laxminarayan; Anne J Mills; Joel G Breman; Anthony R Measham; George Alleyne; Mariam Claeson; Prabhat Jha; Philip Musgrove; Jeffrey Chow; Sonbol Shahid-Salles; Dean T Jamison
Journal:  Lancet       Date:  2006-04-08       Impact factor: 79.321

3.  Mass diethylcarbamazine chemotherapy for control of bancroftian filariasis through community participation: comparative efficacy of a low monthly dose and medicated salt.

Authors:  D W Meyrowitsch; P E Simonsen; W H Makunde
Journal:  Trans R Soc Trop Med Hyg       Date:  1996 Jan-Feb       Impact factor: 2.184

4.  A community-based trial for the control of lymphatic filariasis and iodine deficiency using salt fortified with diethylcarbamazine and iodine.

Authors:  A R Freeman; P J Lammie; R Houston; M D LaPointe; T G Streit; P L Jooste; J M Brissau; J G Lafontant; D G Addiss
Journal:  Am J Trop Med Hyg       Date:  2001-12       Impact factor: 2.345

Review 5.  Iodine deficiency in the world: where do we stand at the turn of the century?

Authors:  F Delange; B de Benoist; E Pretell; J T Dunn
Journal:  Thyroid       Date:  2001-05       Impact factor: 6.568

6.  Ocular findings in a double-blind study of ivermectin versus diethylcarbamazine versus placebo in the treatment of onchocerciasis.

Authors:  K Y Dadzie; A C Bird; K Awadzi; H Schulz-Key; H M Gilles; M A Aziz
Journal:  Br J Ophthalmol       Date:  1987-02       Impact factor: 4.638

7.  Diethylcarbamazine prophylaxis for human loiasis. Results of a double-blind study.

Authors:  T B Nutman; K D Miller; M Mulligan; G N Reinhardt; B J Currie; C Steel; E A Ottesen
Journal:  N Engl J Med       Date:  1988-09-22       Impact factor: 91.245

Review 8.  Diethylcarbamazine salt in the control of lymphatic filariasis.

Authors:  H Gelband
Journal:  Am J Trop Med Hyg       Date:  1994-06       Impact factor: 2.345

9.  Efficacy of diethylcarbamazine medicated salt in interrupting Brugia malayi transmission in hill tribe settlements in Kerala State.

Authors:  S M Kaul; V K Raina; R D Joshi; C N Koya; A Kumar; T Verghese
Journal:  J Commun Dis       Date:  1992-03

10.  Control of Bancroftian filariasis by cooking salt medicated with diethylcarbamazine.

Authors:  F Hawking; R J Marques
Journal:  Bull World Health Organ       Date:  1967       Impact factor: 9.408

View more
  7 in total

1.  A low-tech analytical method for diethylcarbamazine citrate in medicated salt.

Authors:  Abigail Weaver; Patrick Brown; Shannon Huey; Marco Magallon; E Brennan Bollman; Dominique Mares; Thomas G Streit; Marya Lieberman
Journal:  PLoS Negl Trop Dis       Date:  2011-02-08

2.  Increasing coverage in mass drug administration for lymphatic filariasis elimination in an urban setting: a study of Malindi Town, Kenya.

Authors:  Doris W Njomo; Dunstan A Mukoko; Nipher K Nyamongo; Joan Karanja
Journal:  PLoS One       Date:  2014-01-14       Impact factor: 3.240

3.  Assessing endgame strategies for the elimination of lymphatic filariasis: A model-based evaluation of the impact of DEC-medicated salt.

Authors:  Morgan E Smith; Brajendra K Singh; Edwin Michael
Journal:  Sci Rep       Date:  2017-08-07       Impact factor: 4.379

4.  Economic performance and cost-effectiveness of using a DEC-salt social enterprise for eliminating the major neglected tropical disease, lymphatic filariasis.

Authors:  Swarnali Sharma; Morgan E Smith; James Reimer; David B O'Brien; Jean M Brissau; Marie C Donahue; Clarence E Carter; Edwin Michael
Journal:  PLoS Negl Trop Dis       Date:  2019-07-01

5.  Assessing factors influencing communities' acceptability of mass drug administration for the elimination of lymphatic filariasis in Guyana.

Authors:  Reza A Niles; Charles R Thickstun; Horace Cox; Daniel Dilliott; Clara R Burgert-Brucker; Emma M Harding-Esch; Nikita Clementson; Annastacia Sampson; Jean Seme Alexandre; Ana C Morice Trejos; Ronaldo G Carvalho Scholte; Alison Krentel
Journal:  PLoS Negl Trop Dis       Date:  2021-09-20

6.  Haiti National Program for the elimination of lymphatic filariasis--a model of success in the face of adversity.

Authors:  Roland Oscar; Jean Frantz Lemoine; Abdel Nasser Direny; Luccene Desir; Valery E Madsen Beau de Rochars; Mathieu J P Poirier; Ann Varghese; Ijeoma Obidegwu; Patrick J Lammie; Thomas G Streit; Marie Denise Milord
Journal:  PLoS Negl Trop Dis       Date:  2014-07-17

7.  Are Alternative Strategies Required to Accelerate the Global Elimination of Lymphatic Filariasis? Insights From Mathematical Models.

Authors:  Wilma A Stolk; Joaquin M Prada; Morgan E Smith; Periklis Kontoroupis; Anneke S de Vos; Panayiota Touloupou; Michael A Irvine; Paul Brown; Swaminathan Subramanian; Marielle Kloek; E Michael; T Deirdre Hollingsworth; Sake J de Vlas
Journal:  Clin Infect Dis       Date:  2018-06-01       Impact factor: 9.079

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.